Inhibikase grants $2.03 stock options to seven new hires
Inhibikase Therapeutics granted 981,243 stock options to seven new employees at $2.03 per share, effective June 30, 2026. The options vest over four years under Nasdaq Rule 5635(c)(4). The Company focuses on PAH treatments, with its lead candidate IKT-001 in Phase 3 trials.
*this image is generated using AI for illustrative purposes only.
Inhibikase Therapeutics, Inc. granted non-qualified stock options to purchase an aggregate of 981,243 shares of its common stock to seven newly hired non-executive employees. The grants were made under the Company’s 2026 Inducement Equity Plan, effective as of June 30, 2026, as a material inducement to the new employees’ entry into employment. The Compensation Committee of the Company’s Board of Directors approved the inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $2.03 per share, equal to the closing price of the Company’s common stock on the Effective Date. The ten-year term includes a vesting schedule where 25% vests on the first anniversary of the Effective Date, with the remaining 75% vesting in 36 equal monthly installments thereafter. The options are subject to the terms and conditions of the Inducement Plan, which the Board approved in March 2026, and the terms of award agreements covering the grants.
Grant Details
| Detail | Value |
|---|---|
| Total Shares Granted | 981,243 |
| Exercise Price | $2.03 per share |
| Grant Date | June 30, 2026 |
| Term | 10 years |
| Vesting Schedule | 25% at 1 year; 75% monthly over 3 years |
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, specifically Pulmonary Arterial Hypertension (PAH). The Company’s lead product candidate is IKT-001, a prodrug of imatinib mesylate for PAH, an orphan indication. The Company is actively enrolling patients in its pivotal Phase 3 clinical study, IMPROVE-PAH, across approximately 180 sites worldwide.
How will the dilution from these nearly one million new options impact existing shareholders as the company progresses through its pivotal Phase 3 trial?
Does the hiring of seven new non-executive employees signal an expansion in operational capacity to support the approximately 180 active clinical sites?
What are the anticipated cash burn rate implications of these new hires as Inhibikase advances the IMPROVE-PAH study?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
